# Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )

> **NCT03277261** · PHASE3 · COMPLETED · sponsor: **TG Therapeutics, Inc.** · enrollment: 549 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis (RMS)

## Interventions

- **BIOLOGICAL:** Ublituximab
- **DRUG:** Teriflunomide
- **DRUG:** Oral Placebo
- **DRUG:** IV Placebo

## Key facts

- **NCT ID:** NCT03277261
- **Lead sponsor:** TG Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-19
- **Primary completion:** 2020-07-23
- **Final completion:** 2020-11-06
- **Target enrollment:** 549 (ACTUAL)
- **Last updated:** 2021-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03277261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03277261, "Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03277261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*